CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders ...
Cognito Therapeutics and the West Virginia University Rockefeller Neuroscience Institute (RNI), announced today the launch of the first Brain Health Collaboratory, a new model designed to accelerate ...
Collaboration expands national initiative designed to accelerate the discovery, validation, and delivery of non-invasive neuroprotective therapies Cognito Therapeutics, a late clinical-stage ...
Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...
Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics announced a $105 million Series C round ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two ...
CAMBRIDGE, Mass. & NEW ORLEANS, March 25, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in ...
Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced a collaboration with Ochsner Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results